CU researchers have developed a human thyroid cancer cell line with the BRAF V600E mutation. The cell line, called CUTC60, was derived from a 59-year-old female patient with anaplastic thyroid cancer (PTC) and was developed to study tumor progression and response to therapy. The research team verified that the CUTC60 cells form tumors in orthotopic and flank patient-derived xenograft (PDX) mouse models. This cell line creates a new patient-derived model to study advanced thyroid cancer.
Schweppe RE, Pozdeyev N, Pike LA, et al. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Mol Cancer Res. 2019. pii: molcanres.1026.2018. doi: 10.1158/1541-7786.MCR-18-1026.